Investing in Amyris, Inc. (AMRS)  ➔  Intrinsic value

Prev. close$6.78 
ModelValueUpside
Chepakovich$0.00-100%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$6.78  
Valuation MethodValuePotential 
Chepakovich Model$0.00-100%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

Amyris, Inc., a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. It applies technology platform to engineer, manufacture, and sell products for the clean health and beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.